Travel cards could help radiopharma patients avoid delays
April 29, 2020 -- Patients who undergo radiation treatment with lutetium-177 [...]
Noble Registry – iPSMA SPECT Imaging for Prostate Cancer
BRUSSELS, Belgium and MELBOURNE, Australia, 20th of April 2021 – [...]
Doctor, What is Neuroendocrine Cancer?
Waiting for a download is frustrating. Imagine waiting 5+ years [...]
Seeing Cancer Cells, Killing Cancer Cells
Using molecules to safely carry radioactive materials inside the human [...]
Evolving role of Ac-225-PSMA Radioligand Therapy in mCRPC
225Ac-PSMA RLT is an efficacious and safe treatment option for [...]
World Theranostics Day 2021!
Today is World Theranostics Day! On this day in 1941, [...]
How PRRT can Improve Care for Neuroendocrine Tumor Patients
Learn more about how Peptide Receptor Radionuclide Therapy (PRRT) can [...]
Overview of Radiolabeled Somatostatin Analogs for Cancer Imaging and Therapy
With some radiopharmaceuticals now used in clinical practice, somatostatin analogs [...]
Real-world data analysis of efficacy and survival after Lu-177 PSMA in metastatic castration-resistant prostate cancer
177Lu-PSMA radioligand therapy provides a significant response rate with a [...]
PSMA Lu-177 x Ac-225
Available since 2015, the treatment of patients with metastatic castration-resistant [...]